ReviewInternational journal of molecular sciences2019
Natriuretic Peptides in Heart Failure with Preserved Left Ventricular Ejection Fraction: From Molecular Evidences to Clinical Implications.
Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- Prognostic value of natriuretic peptides in heart failure: systematic review and meta-analysis.Heart failure reviews · 2022Pooled it
- Long-term renal outcomes of patients with biopsy-proven malignant hypertension-associated renal thrombotic microangiopathy who are dialysis-independent at baseline.Renal failure · 2026Observational
- Unifying and unique roles of non-coding RNA biomarkers in liver and heart fibrosis.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2026Review
- Venous vascular pharmacology: how does it contribute to heart failure with preserved ejection fraction?European heart journal. Cardiovascular pharmacotherapy · 2026Review
- Relative Contributions of Functional Capacity and Inflammatory Activity to Quality of Life in Heart Failure with Preserved Ejection Fraction.Biomedicines · 2026Article
- Association of nutritional status assessed by the controlling nutritional status score with clinical outcomes in adults with heart failure with preserved ejection fraction.Frontiers in nutrition · 2026Article
- Plasma Ceramide C24:0/C16:0 Relates to Outcomes in Patients With Heart Failure With Preserved Ejection Fraction.JACC. Advances · 2025Article
- Heart Failure With Preserved Ejection Fraction and Low B-type Natriuretic Peptide: A Diagnostic Dilemma.Cureus · 2025Article
- Saudi Heart Association Position Statement on NT-proBNP for Cardiovascular Risk Screening in Asymptomatic Adults With Type 2 Diabetes Mellitus.Journal of the Saudi Heart Association · 2025Article
- Diagnosing and managing patients with heart failure with preserved ejection fraction: a consensus survey.BMJ open · 2024Observational
- Emerging Role of Natriuretic Peptides in Diabetes Care: A Brief Review of Pertinent Recent Literature.Diagnostics (Basel, Switzerland) · 2024Review
- The Value of Biomarkers in Major Cardiovascular Surgery Necessitating Cardiopulmonary Bypass.Reviews in cardiovascular medicine · 2024Review
- Kidney Outcomes Following Angiotensin Receptor-Neprilysin Inhibitor vs Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker Therapy for Thrombotic Microangiopathy.JAMA network open · 2024Article
- Hypoxically stored RBC resuscitation in a rat model of traumatic brain injury and severe hemorrhagic shock.Life sciences · 2024Article
- Novel Strategies in Diagnosing Heart Failure with Preserved Ejection Fraction: A Comprehensive Literature Review.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2024Review
- Advances of research in diabetic cardiomyopathy: diagnosis and the emerging application of sequencing.Frontiers in cardiovascular medicine · 2024Review
- Tic-Tac: A Translational Approach in Mechanisms Associated with Irregular Heartbeat and Sinus Rhythm Restoration in Atrial Fibrillation Patients.International journal of molecular sciences · 2023Review
- Exercise-induced B-lines for the diagnosis of heart failure with preserved ejection fraction: a two-centre study.Clinical research in cardiology : official journal of the German Cardiac Society · 2023Article
- How to Use Natriuretic Peptides in Patients with Heart Failure with Non-Reduced Ejection Fraction?Anatolian journal of cardiology · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of heart failure with preserved ejection fraction (HFpEF) is increasing and its challenging diagnosis and management combines clinical, imagistic and biological data. Natriuretic peptides (NPs) are hormones secreted in response to myocardial stretch that, by increasing cyclic guanosine monophosphate (cGMP), counteract myocardial fibrosis and hypertrophy, increase natriuresis and determine vasodilatation. While their role in HFpEF is controversial, most authors focused on b-type natriuretic peptides (BNPs) and agreed that patients may show lower levels. In this setting, newer molecules with an increased specificity, such as middle-region pro-atrial natriuretic peptide (MR-proANP), emerged as promising markers. Augmenting NP levels, either by NP analogs or breakdown inhibition, could offer a new therapeutic target in HFpEF (already approved in their reduced EF counterparts) by increasing the deficient cGMP levels found in patients. Importantly, these peptides also retain their prognostic value. This narrative review focuses on NPs' physiology, diagnosis, therapeutic and prognostic implication in HFpEF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.